LET’S TALK ABOUT
MEALTIME CONTROL
CHANGE THE CONVERSATION
WITH INHALED INSULIN

img
img

Explore the following topics today:

  • Understand treatment limitations
  • A unique time action profile
  • Type 1 and type 2 diabetes patient profiles
  • Access + support information
  • Dosing information and safety profiles
Click to Start Exploring
Not actual patients.
img
LET’S TALK ABOUT

PATIENTS LIKE SARAH

A patient with
type 1 diabetes
struggling
to maintain
glycemic control

Learn more about
patients like Sarah
img
LET’S TALK ABOUT

PATIENTS LIKE JASON

A patient with
type 2 diabetes
struggling
to maintain
glycemic control

Learn more about
patients like Jason
REFERENCES
  • Afrezza (insulin human) Inhalation Powder Prescribing Information. MannKind Corporation.
  • Akturk HK, Snell-Bergeon JK, Rewers A, et al. Improved postprandial glucose with inhaled Technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: the STAT study. Diabetes Technol Ther. 2018;20(10):639–647.
  • Lasalle JR, Berria R. Insulin therapy in type 2 diabetes mellitus: a practical approach for primary care physicians and other health care professionals. J Am Osteopath Assoc. 2013;113(3):152–162.
  • Rave K, Heise T, Heinemann L, et al. Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol. 2008;2(2):205–212.
  • Rossetti P, Porcellati F. Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes. Diabetes Care. 2008;31(2):S113–S120.
  • Peyrot M, Rubin RR, Kruger DF, et al. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240–245.
  • Bode BW, McGill JB, Lorber DL, et al. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015;38(12):2266–2273.
  • Rosenstock J, Franco D, Korpachev V, et al. Inhaled Technosphere insulin versus inhaled Technosphere placebo in insulin-naive subjects with type 2 diabetes inadequately controlled on oral antidiabetes agent. Diabetes Care. 2015;38(12):2274–2281.
  • Data on file. MannKind Corporation.
  • Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375(9733):2244–2253.
  • Riddle MC. Basal glucose can be controlled, but the prandial problem persists–it’s the next target! Diabetes Care. 2017;40(3):291-300.
  • Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11)3411-3417.
  • Boss AH, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin. J Diabetes Sci Technol. 2012;6(4):773-779.
img
TYPE2

Would you like to review

jason’s patient profile?

Yes, pleaseNo, thank you
img
img
TYPE1

Would you like to review

SARAH’s patient profile?

Yes, pleaseNo, thank you
img